ArticleNature communications2026
L-type pyocins inhibit the BAM complex to kill without cell entry.
Fabian Munder, Matthew D Johnson, Imogen Samuels, Laura McCaughey, Oleksii Zdorevskyi, Chunxiao Wang, Ashleigh Kropp, Lauren Zavan, Erin P Price, Derek S Sarovich and 10 more
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Fabian MunderDepartment of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.ORCID 0009-0005-5327-3138 Matthew D Johnson *Centre for Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia.
Imogen Samuels *Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC, Australia.
Laura McCaughey *School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Chunxiao WangDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC, Australia.
Ashleigh KroppDepartment of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Lauren ZavanDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0003-4700-3033 Derek S SarovichSunshine Coast Health Institute, Birtinya, QLD, Australia.
Swati VarshneyBio21 Mass Spectrometry and Proteomics Facility, University of Melbourne Bio21 Molecular Science and Biotechnology Institute, Parkville, VIC, Australia.
Christopher A McDevittDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0003-1596-4841 Hari VenugopalRamaciotti Centre for Cryo-Electron Microscopy, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.ORCID 0000-0001-5230-2973 Matthew T DoyleSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Darlington, NSW, Australia.ORCID 0000-0002-1876-1209 Francesca ShortDepartment of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.ORCID 0000-0002-0025-4858 Debnath GhosalCentre for Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia.ORCID 0000-0002-2227-0330 James P R ConnollyNewcastle University Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK.ORCID 0000-0002-0394-3413 Gavin J KnottDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.ORCID 0000-0002-9007-6273 Rhys GrinterDepartment of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia. rhys.grinter@monash.edu.ORCID 0000-0002-8195-5348 Funding
Department of Education and Training | Australian Research Council (ARC) DP230102150Department of Health | National Health and Medical Research Council (NHMRC) APP1197376
6 · The paper itselfAbstract
Many antibiotics are ineffective against the Gram-negative pathogen Pseudomonas aeruginosa because of intrinsic defence mechanisms, such as the impermeable bacterial outer membrane. Here, we show that protein antibiotics called L-type pyocins kill P. aeruginosa by inhibiting the β-barrel assembly machinery (BAM) complex at the cell surface, halting outer-membrane protein assembly. Using single-particle cryo-electron microscopy, we show that L-type pyocins bind a surface-exposed region of BamA and deploy a C-terminal peptide that competitively inhibits the BAM complex, demonstrating that cell entry is not required for antibiotic activity. We combine genetics, multi-omics and cryo-electron tomography to show that BAM complex inhibition by L-type pyocins or the cyclic-peptide antibiotic, darobactin, triggers a multifaceted transcriptomic, proteomic, and morphological response. BAM inhibition ultimately leads to a catastrophic loss of membrane integrity and cell death. These results validate BAM as a target for antibiotics that do not enter the cell and define an engineerable system for their development.
Indexed as
Anti-Bacterial AgentsBacterial Outer Membrane ProteinsPseudomonas aeruginosaPyocinsCryoelectron MicroscopyProteomicsAnti-Bacterial AgentsBacterial Outer Membrane ProteinsPyocins
Identifiers
PMID42393045
PMCPMC13463100
What OpenQuestion holds
Textmetadata
Read underepoch 390